PhotoMedex develops laser therapy for vitiligo:
This article was originally published in Clinica
PhotoMedex has submitted an 510(k) clearance application to the FDA for permission to market its XTRAC laser system for the treatment of vitiligo, a skin disease that causes a loss of pigmentation and which, the company says, affects around 2-4 million people in the US. The Radnor, Pennsylvania-based company's excimer laser system is already FDA-approved for treating psoriasis.
You may also be interested in...
Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.
Three accelerated assessment requests will either be granted or rejected this week at the European Medicines Agency.
A new work sharing pilot has been launched to evaluate jointly generic drugs intended for launch in Singapore and Malaysia.